### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Johan Stenflo

Application No.: 09/890,949

Filing Date:

September 10, 2001

Title: MONOCLONAL ANTIBODY

OCT 1 5 2004

Group Art Unit: 1641

Examiner: CHANGHWA J. CHEU

Confirmation No.: 9510

OCT 19 2004

# THIRD **INFORMATION DISCLOSURE STATEMENT** TRANSMITTAL LETTER

T. CENTER 1600/2800

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

$\overline{}$	٠			
┖.		r	•	
. 7	ı			

	sed is a for the above-	THIRD identified pater	Information	on Dis	closure Statement and	accompanying form
X TI A A S C X A	<ul> <li>No additional fee for submission of an IDS is required.</li> <li>The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.</li> <li>A statement under 37 C.F.R. § 1.97(e) is also enclosed.</li> <li>A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R § 1.17(p) are also enclosed.</li> <li>Charge to Deposit Account No. 02-4800 for the fee due.</li> <li>A check in the amount of\$180.00 is enclosed for the fee due.</li> </ul>					
1.21 that m	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.					
				Res	pectfully submitted,	
				BUF	RNS, DOANE, SWECK	ER & MATHIS, L.L.P.
P.O. Box 14 Alexandria, (703) 836-6	Virginia 2231	3-1404		Ву	Deborah H. Yellin	l
Date: Octo	ber 15, 2004				Registration No. 45,9	904

## Attorney Docket No.

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Johan Stenflo

Application No.: 09/890,949

Filing Date:

Title: MONOCLONAL ANTIBODY

OCT 1 5 2004 September 10, 200 PRANE

Group Art Unit: 1641

Examiner: CHANGHWA J. CHEU

Confirmation No.: 9510

OCT 19 2004

### **THIRD** INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

TECH CENTER 1600/2900

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

$\overline{}$	٠		
		п	••
. 7	ı		

Sir:	
РТС	Enclosed is a THIRD Information Disclosure Statement and accompanying form 1-1449 for the above-identified patent application.
	<ul> <li>No additional fee for submission of an IDS is required.</li> <li>The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.</li> <li>A statement under 37 C.F.R. § 1.97(e) is also enclosed.</li> <li>A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.</li> <li>Charge to Deposit Account No. 02-4800 for the fee due.</li> <li>A check in the amount of\$180.00 is enclosed for the fee due.</li> <li>Charge to credit card. Form PTO-2038 is attached.</li> </ul>
	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. paper is submitted in duplicate.
	Respectfully submitted,
	BURNS, DOANE, SWECKER & MATHIS, L.L.P.
Alex	Box 1404 (andria, Virginia 22313-1404 (b) 836-6620 (b) By
Date	Deborah H. Yellin Control Registration No. 45 904

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Johan Stenflo

Application No.: 09/890,949

Filed: September 10, 2001

For: MONOCLONAL ANTIBODY

Group Art Unit: 1641

Examiner: CHANGHWA J. CHEU

Confirmation No.: 9510

OCT 19 2004

# THIRD INFORMATION DISCLOSURE STATEMENT

**TECH CENTER 1600/2900** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

I, the undersigned, hereby state that no item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date October 15, 2004

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

VA 446380.1

By:

Deborah H. Yellih Registration No. 45,904

10/18/2004 HVUONG1 00000021 09890949

01 FC:1806

180.00 OP

# THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

(use as many sheets as necessary)

1 of 1

Complete if Known				
Application Number	09/890,949			
Filing Date	September 10, 2001			
First Named Inventor	Johan Stenflo			
Examiner Name	CHANGHWA J. CHEU			
<b>Attorney Docket Number</b>	003300-816			

U.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)	
101	36				
1	5 2004 5		ACT 4 0 0004		
PER TRA	NEMACOV P.		OCT 19 2004		
The Nade	Page Andrew		TECH CENTER 1600/2900		

FOREIGN PATENT DOCUMENTS											
					STATUS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
						ļ					
									ļ		

Examiner	Include name of the pathog (in CARITAL LETTERS) title of the patient (when a property) title of the item (but all many)
Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	SUZUKI, Koji et al., "Characterization of a cDNA for Human Protein C Inhibitor", The Journal of Biological
	Chemistry, April 24, 1986, Vol. 262, No. 2, The American Society of Biological Chemists, Inc., Bethesda, MI
	GETTINS, Peter G. W., "Serpin Structure, Mechanism, and Function", Chemical Reviews, Vol. 102, Number
	12, pp. 4751-4803, Department of Biochemistry & Molecular Genetics, Chicago, IL.
	HUNTINGTON, James et al., "Crystal Structure of Protein C Inhibitor Provides Insights into Hormone
	Binding and Heparin Activation", Structure, February, 2003, Vol. 11, pp. 205-215, Elsevier Science, Ltd.,
	Cambridge, MA.

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.